US Bioservices now dispenses BRAFTOVI and MEKTOVI

June 27, 2018

The U.S. Food and Drug Administration recently approved BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.